Drugmaker VIVUS (NASDAQ:VVUS) has struggled to ramp up sales of its recently approved obesity medication Qsymia. With competition from Arena Pharmaceuticals (NASDAQ:ARNA) and its partner Eisai (NASDAQOTH:ESALY) looming once their drug Belviq clears DEA scheduling, VIVUS has launched the Save Now! program. In this video, health care analyst Max Macaluso discusses how this new program will impact VIVUS' business and how it might affect the competitive landscape of the obesity market.

Editor's note: This video was filmed on March 5, 2013.

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.